中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性HBV感染免疫耐受期应重新评估诊断标准并将研究重点着眼于>35岁人群

周乙华

引用本文:
Citation:

慢性HBV感染免疫耐受期应重新评估诊断标准并将研究重点着眼于>35岁人群

DOI: 10.3969/j.issn.1001-5256.2021.07.007
利益冲突声明:作者声明不存在利益冲突。
详细信息
    通信作者:

    周乙华,zgr03summer@126.com

  • 中图分类号: R512.62

Diagnostic criteria should be reevaluated in immune-tolerant phase of chronic hepatitis B virus infection and research should be focused on the population aged > 35 years

  • [1] CUI F, SHEN L, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477.
    [2] LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741.
    [3] KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
    [4] KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075.
    [5] van WOLLEGHEM T, HOU J, van OORD G, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells[J]. Hepatology, 2015, 62(1): 87-100. DOI: 10.1002/hep.27805.
    [6] HONG M, BERTOLETTI A. Tolerance and immunity to pathogens in early life: Insights from HBV infection[J]. Semin Immunopathol, 2017, 39(6): 643-652. DOI: 10.1007/s00281-017-0641-1.
    [7] SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52(8): 1399-1406. DOI: 10.1111/apt.16067.
    [8] ZENG HM, HAO J, CAO MM, et al. Trend analysis of age of diagnosis for liver cancer in cancer registry areas of China, 2000-2014[J]. Chin J Prev Med, 2018, 52(6): 573-578. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.004.

    曾红梅, 赫捷, 曹毛毛, 等. 2000—2014年中国肿瘤登记地区肝癌发病年龄变化趋势分析[J]. 中华预防医学杂志, 2018, 52(6): 573-578. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.004.
    [9] WEI KP, ZHU FC, LIU JX, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study[J]. Vaccine, 2018, 36(2): 256-263. DOI: 10.1016/j.vaccine.2017.11.037.
    [10] LOU HQ, ZHU JH, WANG ZH, et al. Real-world efficacy of immunoprophylaxis against mother-to-infant transmission of hepatitis B virus based on puerperant population[J]. Chin J Perinat Med, 2019, 22(8): 591-596. DOI: 10.3760/cma.j.issn.1007-9408.2019.08.011.

    娄海琴, 朱继华, 王志红, 等. 以产妇人群为基础的免疫预防乙型肝炎病毒母婴传播的现实世界效果[J]. 中华围产医学杂志, 2019, 22(8): 591-596. DOI: 10.3760/cma.j.issn.1007-9408.2019.08.011.
    [11] HUANG H, XU C, LIU L, et al. Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus[J]. Clin Infect Dis, 2020. DOI: 10.1093/cid/ciaa898.[Online ahead of print]
    [12] HU Y, FENG Z, LIU J, et al. Virological determinants of spontaneous postpartum e antigen seroconversion and surface antigen seroclearance in pregnant women infected with hepatitis B virus[J]. Arch Med Res, 2016, 47(3): 207-213. DOI: 10.1016/j.arcmed.2016.06.008.
  • 加载中
计量
  • 文章访问数:  371
  • HTML全文浏览量:  84
  • PDF下载量:  82
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-20
  • 录用日期:  2021-05-28
  • 出版日期:  2021-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回